

**Table S4. Primers used in this study.**

<b>Primer</b>	<b>Sequence<sup>a,b,c</sup></b>	<b>Source</b>
<b>Cloning /deletion/sequencing</b>		
1726	5'-CTCTGGATCGCCTTCTCGTA	This study
1727	5'-TCAGAGCGCTTTTGAAGCTAATTCGAGATCGCGCTGAAGAACAAC	This study
1728	5'-AGGAACTTCAAGATCCCCAATTCGGCTCTCGACCACCCAGTTCT	This study
1729	5'-GTACGAGCGCCTATCTGGTC	This study
1791	5'-CGACGCATCGCGATGGAAAC	This study
1790	5'-ATGGACCGGCTGCAAGCCAT	This study
1966	5'-CTTCCGGCCTCTTTTCTTTC	(1)
1967	5'-GTGCTGATCGAGCAGATGAC	(1)
1989	5'-GGAAGTACGCGGACTTCGC	This study
1990	5'-GCATCAACCTCGGCTACACG	This study
2323	5'-CCAGATCAACGACATCATGG	This study
2324	5'-CGAGCATATAGCCCGATACC	This study
2570	5'-GGATGACTTCGGCGCTATC	This study
2571	5'-CCGTTCAACCTGACCTCAAC	This study
2572	5'-GTCTTCCGCCAGCGCTAC	This study
2573	5'-AAGCCGATTCATCTGGACAC	This study
2575	5'-CGTCGATGCGGTCTATACG	This study
2576	5'-ATCGAAGCTCGGCAGGTG	This study
2577	5'-CGCGCCTACGAGGAGTTC	This study
2592	5'-CTCGCTCACGCTGATTGC	This study
2607	5'-CGCTCGGGATGTCGCGCGCGTGC	This study
2608	5'-CGACGCGCGCGACATCCCGAGCG	This study
2618	5'-CCTGAAGCAGCAACAGCAC	This study
2619	5'-TCAGAGCGCTTTTGAAGCTAATTCGATATCGATAGCGCCGAAGTC	This study
2620	5'-GACTTCGGCGCTATCGATATCGAATTAGCTTCAAAGCGCTCTGA	This study
2621	5'-GCTTCCTTCGCTTCGATGCGAATTGGGGATCTTGAAGTACCT	This study
2622	5'-AGGTA <del>CTT</del> CAAGATCCCCAATTCGCATCGAAGCGAAGGAAGC	This study
2623	5'-CTTTCGCGTGAACGATCC	This study
2636	5'-AGCGAATAATCGACCGACAC	This study
2637	5'-GATGACGGACGAGGAAAGC	This study
2638	5'-CCAATATCGCGGAGGTAGAGCGGTTAGTCGCGCAGACG	This study
2639	5'-TCACTGCTTGCCGTCCAAGCTTAGGTGTTTCGTCAGGTTGACC	This study
2640	5'-CGAGCCGCGACGAAG	This study
2641	5'-CATCGACCACGGCACG	This study
2642	5'-GGTCAACCTGACGAACACCTAAGCTTGGACGGCAAGCAGTGA	This study
2643	5'-CGTCTGCGGACTAACCCTCTACCTCCGCGATATTGG	This study
<b>P1 promoter expression constructs</b>		
1563	5'-GGGATATCGAATTCACGAACCCAGTTGAC	This study
1789	5'-ATGGCTTGCAGCCGGTCCATGTCGAATCCTTCTTGTGAATC	This study
1790	5'-ATGGACCGGCTGCAAGCCAT	This study
1791	5'-CGACGCATCGCGATGGAAAC	This study
2702	5'-AAGCTTTTGACATAAGCCTGTTCGGTTCG	This study
2693	5'-GGTACCTACGCGGCCACCTGC	This study
2694	5'-GCATGGACCCGATTCAGGCAAT	This study
2696	5'-GCGGTCCATGCCATCAATCCTTCTTGTGAATC	This study
2871	5'-ATGGACCGCATTCAAGCAATGGAAGTCTTC	This study

**Table S4. Continued.**

<b>Primer</b>	<b>Sequence</b>	<b>Source</b>
<b>Real time PCR primers</b>		
Bp23S_F	5'-GTAGACCCGAAACCAGGTGA	(2)
Bp23S_R	5'-CACCCCTATCCACAGTCAT	(2)
1524 ( <i>bpeF</i> )	5'-TCCGAGTATCCGGAAGTCGT	(2)
1525 ( <i>bpeF</i> )	5'-GTCCTCGACACCGTTGATCT	(2)
1814 ( <i>bpeT</i> )	5'-GAGCTTTCAGGTCAACAACC	(1)
1815 ( <i>bpeT</i> )	5'-GTGAGTGGAATTCGCAGAG	(1)
2779 ( <i>bpeS</i> )	5'-AAGCGCTCAGGTAATCGGG	This study
2780 ( <i>bpeS</i> )	5'-GGTCGAAGAGGGGATCGATTG	This study
<b>Tn7 integration confirmation</b>		
Tn7L	5'-ATTAGCTTACGACGCTACACCC	(3)
BPGLMS1	5'-GAGGAGTGGGCGTCGATCAAC	(3)
BPGLMS2	5'-ACACGACGCAAGAGCGGAATC	(3)
BPGLMS3	5'-CGGACAGGTTTCGCGCCATGC	(3)

<sup>a</sup>Bold indicates a newly generated restriction enzyme cleavage site.

<sup>b</sup>Underline indicates a homologous splicing region.

<sup>c</sup>Italic type indicates a nucleotide change.

## References

1. **Podnecky NL, Wuthiekanun V, Peacock SJ, Schweizer HP.** 2013. The BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental *Burkholderia pseudomallei* isolates. *Antimicrob Agents Chemother* **57**:4381-4386.
2. **Kumar A, Mayo M, Trunck LA, Cheng AC, Currie BJ, Schweizer HP.** 2008. Expression of resistance-nodulation-cell division efflux pumps in commonly used *Burkholderia pseudomallei* strains and clinical isolates from Northern Australia. *Trans Roy Soc Trop Med Hyg* **102 (Suppl 1)**:S145-S151.
3. **Choi K-H, Mima T, Casart Y, Rholl D, Kumar A, Beacham IR, Schweizer HP.** 2008. Genetic tools for select agent compliant manipulation of *Burkholderia pseudomallei*. *Appl Env Microbiol* **74**:1064-1075.